06/23/22 8:00 AMAMEX : TMBR clinical trialTimber Pharmaceuticals Announces First Patients Enrolled in Phase 3 ASCEND Clinical Trial Evaluating TMB-001 in Congenital Ichthyosisvia NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or theRHEA-AIvery positive
05/31/22 8:00 AMAMEX : TMBR Timber Pharmaceuticals Receives FDA Breakthrough Therapy Designation for TMB-001 for the Treatment of Congenital Ichthyosisvia NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on theRHEA-AIpositive
05/12/22 4:10 PMAMEX : TMBR earningsTimber Pharmaceuticals Provides Business Update and Announces First Quarter 2022 Financial ResultsTimber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focusedRHEA-AIvery positive
04/28/22 8:00 AMAMEX : TMBR Timber Pharmaceuticals Announces Fast Track Designation Granted by FDA for TMB-001 in Severe Subtypes of Congenital Ichthyosisvia NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceuticalRHEA-AIvery positive
03/31/22 5:44 PMAMEX : TMBR earningsTimber Pharmaceuticals Provides Business Update and Announces Fourth Quarter and Year End 2021 Financial ResultsTimber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization ofRHEA-AIvery positive
03/25/22 8:00 AMAMEX : TMBR Timber Pharmaceuticals Announces Late-Breaking Presentation at the American Academy of Dermatology 2022 Annual MeetingTimber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), aRHEA-AIpositive
02/03/22 8:00 AMAMEX : TMBR clinical trialTimber Pharmaceuticals Announces Positive End-of-Phase 2 Meeting with FDA for TMB-001 in Moderate to Severe Congenital IchthyosisTimber Pharmaceuticals, Inc. ("Timber" or theRHEA-AIneutral
01/06/22 8:00 AMAMEX : TMBR conferencesTimber Pharmaceuticals to Present at H.C. Wainwright BioConnect ConferenceTimber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rareRHEA-AIneutral
11/17/21 4:18 PMAMEX : TMBR conferencesclinical trialTimber Pharmaceuticals to Host Conference Call Discussing Positive Topline Results from Phase 2b CONTROL Study of Congenital Ichthyosis for Lead Asset, TMB-001Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization ofRHEA-AIneutral
11/15/21 4:15 PMAMEX : TMBR earningsTimber Pharmaceuticals Provides Business Update and Announces Third Quarter 2021 Financial ResultsTimber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), aRHEA-AIvery positive